{"id":"cd40","name":"CD40","symbol":"CD40","route":"/targets/cd40/","asOf":"2026-09-24","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11919","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101017","uniprot":"https://www.uniprot.org/uniprotkb/P25942/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P25942","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1250358","open-targets":"https://platform.opentargets.org/target/ENSG00000101017","civic":"https://civicdb.org/genes/958/summary","oncokb":"https://www.oncokb.org/gene/CD40","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD40","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD40","depmap":"https://depmap.org/portal/gene/CD40?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000101017-CD40","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/958","omim":"https://www.omim.org/entry/109535"}],"products":[{"id":"mitazalimab","name":"Mitazalimab","status":"phase-2","modality":"Monoclonal antibody (CD40 agonist)","route":"/drugs/mitazalimab/"},{"id":"ng-350a","name":"NG-350A","status":"phase-1","modality":"Oncolytic adenovirus (T-SIGn), given into a vein, carrying a transgene","route":"/drugs/ng-350a/"},{"id":"selicrelumab","name":"Selicrelumab","status":"phase-2","modality":"Monoclonal antibody (CD40 agonist)","route":"/drugs/selicrelumab/"},{"id":"sv-102","name":"SYNC-T Therapy SV-102","status":"phase-2","modality":"Intratumoral multi-agent immunotherapy given with partial cryolysis (drug-device combination)","route":"/drugs/sv-102/"}],"trials":[{"id":"nct07199764","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","nct":"NCT07199764","phase":"2","status":"recruiting"},{"id":"nct03424005","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","nct":"NCT03424005","phase":"1/2","status":"recruiting"},{"id":"nct04888312","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","nct":"NCT04888312","phase":"1/2","status":"active"},{"id":"nct03852511","name":"First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)","nct":"NCT03852511","phase":"1","status":"completed"},{"id":"nct06459869","name":"NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","nct":"NCT06459869","phase":"1","status":"active"},{"id":"nct05544227","name":"Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer","nct":"NCT05544227","phase":"1","status":"completed"},{"id":"nct05165433","name":"Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)","nct":"NCT05165433","phase":"1","status":"completed"}],"pathways":[],"companies":["akamis-bio","alligator-bioscience","immunoah","flatiron-health","syncromune"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}